Zhu ZhiYun – General Manager, Zambon China
Zhu ZhiYun, general manager of Zambon China, shares the growth of Zambon China from a manufacturing facility – when he joined in 2005 – to the fully-fledged commercial affiliate it…
Founded in 1988, the China Pharmaceutical Innovation and Research Development Association (PhIRDA) is registered as a non-profit organization by the Ministry of Civil Affairs of China at the first national level. PhIRDA will exert great effort on “academia-industry collaboration”, which centres on the principle of “innovation, industrialization, internationalization” and persists in innovation to achieve unmet clinical requirements.
Currently, PhIRDA has 142 members, which mainly consist of five major categories: First, start-up and R&D enterprises focusing on innovation of pharmaceutical products; Second, domestic first-class universities, colleges and research institutions conducting pharmaceutical research and development; Third clinical institutions featuring high skills in applicable research on new drugs, especially those that undertake “major new drug innovation” technological platform for good clinical practice; Fourth, investment institutions committing to pharmaceutical innovation; Fifth, national pharmaceutical enterprises excelling at innovation; Moreover, PhIRDA has established a Drug R&D Specialty Committee, Clinical Research Specialty Committee, Medicinal Policy Specialty Committee and Pharmaceutical Innovation Investment Specialty Committee, in order to promote innovation as the goal of organizational structure.
PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.
Contact
Address: Room 601, CTYS Plaza, No. 5 Dongzhimen South Street, Dongcheng District, Beijing, P.R. CHINA
Tel: +86 10-58156353
Email: luxt@phirda.com, ruanxx@phirda.com
Zhu ZhiYun, general manager of Zambon China, shares the growth of Zambon China from a manufacturing facility – when he joined in 2005 – to the fully-fledged commercial affiliate it…
Dr Tianyi (Tee) Zhang, GM of Frontage China and SVP of Frontage Holdings, shares the significant growth of the China affiliate over the past four years; their competitive advantages in…
Dr Jiang Lei and Dr Shou Jianyong, EnnovaBio’s co-founders, introduce their strategy and outline the progress being made in the Chinese biopharma industry at large. We are a Chinese…
Dr Shun Luo, chairman, founder and CEO of Thousand Oaks Biopharmaceuticals, shares the company’s vision to deliver more accessible and affordable biologics to patients globally by lowering the cost of…
Catherine Lee, general manager and managing director of West Pharmaceutical Services China, shares the highlights of her 2.5 years heading West’s China affiliate; West’s commitment to delivering their global scientific…
Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high…
Dr Jinzi Jason Wu of Ascletis – a Chinese biotech success story that has developed rapidly in recent years – outlines the company’s journey from its founding in 2013 to…
PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in…
More accessible and affordable healthcare for all: China’s government has outlined several proposals to expand healthcare reform in a report released 4th June by the General Office of the State…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the…
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the…
See our Cookie Privacy Policy Here